N Shaikh1, A Gupte2, S Dharmshale3, S Pokkali4, M Thakar1, V J Upadhye5, A A Ordonez4, A Kinikar3, N Gupte6, V Mave6, A Kagal3, A Gupta7, A Lalvani5, R Paranjpe1, R Bharadwaj3, S K Jain4. 1. National AIDS Research Institute, Pune, India. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Byramjee Jeejeebhoy Government Medical College, Pune, India. 4. Department of Pediatrics, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Imperial College, London, UK. 6. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, Byramjee Jeejeebhoy Government Medical College, Pune, India. 7. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
SETTING: The tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used as supportive evidence to diagnose active tuberculosis (TB). Novel IGRAs could improve diagnosis, but data are lacking in young children. DESIGN: Children (age 5 years) with suspected TB were prospectively screened at a tertiary hospital in Pune, India; the children underwent TST, and standard (early secretory antigenic target 6 and culture filtrate protein 10) and enhanced (five additional novel antigens) enzyme-linked immunospot (ELISpot) assays. RESULTS: Of 313 children (median age 30 months) enrolled, 92% had received bacille Calmette-Guérin vaccination, 53% were malnourished and 9% were coinfected with the human immunodeficiency virus (HIV); 48 (15%) had TB, 128 (41%) did not, and TB could not be ruled out in 137 (44%). The sensitivity of enhanced (45%) and standard (42%) ELISpot assays for diagnosing TB was better than that of TST (20%) (P 0.03); however, enhanced ELISpot was not more sensitive than the standard ELISpot assay (P = 0.50). The specificity of enhanced ELISpot, standard ELISpot and TST was respectively 82% (95%CI 74-89), 88% (95%CI 81-94) and 98% (95%CI 93-100). Rv3879c and Rv3615c, previously reported to be promising antigens, failed to improve the diagnostic performance of the ELISpot assay. CONCLUSION: The TST and the standard and novel ELISpot assays performed poorly in diagnosing active TB among young children in India.
SETTING: The tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used as supportive evidence to diagnose active tuberculosis (TB). Novel IGRAs could improve diagnosis, but data are lacking in young children. DESIGN:Children (age 5 years) with suspected TB were prospectively screened at a tertiary hospital in Pune, India; the children underwent TST, and standard (early secretory antigenic target 6 and culture filtrate protein 10) and enhanced (five additional novel antigens) enzyme-linked immunospot (ELISpot) assays. RESULTS: Of 313 children (median age 30 months) enrolled, 92% had received bacille Calmette-Guérin vaccination, 53% were malnourished and 9% were coinfected with the human immunodeficiency virus (HIV); 48 (15%) had TB, 128 (41%) did not, and TB could not be ruled out in 137 (44%). The sensitivity of enhanced (45%) and standard (42%) ELISpot assays for diagnosing TB was better than that of TST (20%) (P 0.03); however, enhanced ELISpot was not more sensitive than the standard ELISpot assay (P = 0.50). The specificity of enhanced ELISpot, standard ELISpot and TST was respectively 82% (95%CI 74-89), 88% (95%CI 81-94) and 98% (95%CI 93-100). Rv3879c and Rv3615c, previously reported to be promising antigens, failed to improve the diagnostic performance of the ELISpot assay. CONCLUSION: The TST and the standard and novel ELISpot assays performed poorly in diagnosing active TB among young children in India.
Authors: John Z Metcalfe; Charles K Everett; Karen R Steingart; Adithya Cattamanchi; Laurence Huang; Philip C Hopewell; Madhukar Pai Journal: J Infect Dis Date: 2011-11-15 Impact factor: 5.226
Authors: A Lalvani; A A Pathan; H McShane; R J Wilkinson; M Latif; C P Conlon; G Pasvol; A V Hill Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405
Authors: Kurt Schopfer; Hans L Rieder; Thomas Bodmer; Jacqueline F Steinlin-Schopfer; Yay Chantana; Peter Studer; Denis Laurent; Beat Richner Journal: Eur J Pediatr Date: 2013-09-25 Impact factor: 3.183
Authors: B Kampmann; E Whittaker; A Williams; S Walters; A Gordon; N Martinez-Alier; B Williams; A M Crook; A-M Hutton; S T Anderson Journal: Eur Respir J Date: 2009-02-05 Impact factor: 16.671
Authors: Bryan Vonasek; Tara Ness; Yemisi Takwoingi; Alexander W Kay; Susanna S van Wyk; Lara Ouellette; Ben J Marais; Karen R Steingart; Anna M Mandalakas Journal: Cochrane Database Syst Rev Date: 2021-06-28